Compare, Analyse Lupin with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ADCOCK INGRAM (S. Africa) - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   ADCOCK INGRAM
EQUITY SHARE DATA
    LUPIN
Mar-20
ADCOCK INGRAM
Jun-14
LUPIN/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs882373-   
Low Rs505269-   
Sales per share (Unadj.) Rs339.4111.1-  
Earnings per share (Unadj.) Rs-5.9-28.0-  
Cash flow per share (Unadj.) Rs15.5-23.2-  
Dividends per share (Unadj.) Rs6.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs276.787.2-  
Shares outstanding (eoy) m453.00168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.9 70.6%   
Avg P/E ratio x-116.6-11.5 1,015.7%  
P/CF ratio (eoy) x44.8-13.9 -323.6%  
Price / Book Value ratio x2.53.7 68.0%  
Dividend payout %-100.90-   
Avg Mkt Cap Rs m314,20154,239 579.3%   
No. of employees `00018.34.3 426.3%   
Total wages/salary Rs m29,8683,404 877.4%   
Avg. sales/employee Rs Th8,400.64,366.6 192.4%   
Avg. wages/employee Rs Th1,632.0793.0 205.8%   
Avg. net profit/employee Rs Th-147.2-1,100.3 13.4%   
INCOME DATA
Net Sales Rs m153,74818,746 820.2%  
Other income Rs m4,838131 3,685.1%   
Total revenues Rs m158,58518,877 840.1%   
Gross profit Rs m24,849-3,249 -764.9%  
Depreciation Rs m9,702809 1,199.2%   
Interest Rs m3,630508 714.8%   
Profit before tax Rs m16,355-4,434 -368.8%   
Minority Interest Rs m4-12 -31.6%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,571277 4,176.2%   
Profit after tax Rs m-2,694-4,724 57.0%  
Gross profit margin %16.2-17.3 -93.3%  
Effective tax rate %70.8-6.2 -1,132.3%   
Net profit margin %-1.8-25.2 7.0%  
BALANCE SHEET DATA
Current assets Rs m154,13213,730 1,122.6%   
Current liabilities Rs m92,2527,725 1,194.2%   
Net working cap to sales %40.232.0 125.6%  
Current ratio x1.71.8 94.0%  
Inventory Days Days82111 74.0%  
Debtors Days Days129124 104.3%  
Net fixed assets Rs m89,0828,003 1,113.1%   
Share capital Rs m90687 1,041.0%   
"Free" reserves Rs m124,4610-   
Net worth Rs m125,36714,714 852.1%   
Long term debt Rs m17,9335,171 346.8%   
Total assets Rs m249,83927,795 898.9%  
Interest coverage x5.5-7.7 -71.2%   
Debt to equity ratio x0.10.4 40.7%  
Sales to assets ratio x0.60.7 91.2%   
Return on assets %0.4-15.2 -2.5%  
Return on equity %-2.1-32.1 6.7%  
Return on capital %8.7-19.8 -44.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m31,9800-   
CASH FLOW
From Operations Rs m14,6881,600 918.0%  
From Investments Rs m11,070-491 -2,253.1%  
From Financial Activity Rs m-8,9064,693 -189.8%  
Net Cashflow Rs m16,8535,801 290.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.15 Rs / ZAR

Compare LUPIN With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare LUPIN With: ALEMBIC PHARMA  UNICHEM LAB  STRIDES PHARMA SCIENCE  AJANTA PHARMA  FRESENIUS KABI ONCO.  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views On News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This... (Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun (Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel Views On News (Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

LUPIN SHARE PRICE


Apr 13, 2021 (Close)

TRACK LUPIN

MORE ON LUPIN

LUPIN - ASTRAZENECA PHARMA COMPARISON

COMPARE LUPIN WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS